Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?

Abstract Understanding the contribution of imbalance in protein acetylation levels and dysfunction of transcription to neurodegenerative diseases provides the rationale for the use of epigenetic modulators such as histone deacetylase (HDAC) inhibitors to combat neurodegenerative conditions. It is no...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuropathology and experimental neurology 2018-10, Vol.77 (10), p.855-870
Main Authors: Ziemka-Nalecz, Malgorzata, Jaworska, Joanna, Sypecka, Joanna, Zalewska, Teresa
Format: Article
Language:English
Subjects:
Neurodegeneration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4913-dc13d360f32e501cd767b78002845c56444e86cb7fa8517602a4d05a601241883
cites cdi_FETCH-LOGICAL-c4913-dc13d360f32e501cd767b78002845c56444e86cb7fa8517602a4d05a601241883
container_end_page 870
container_issue 10
container_start_page 855
container_title Journal of neuropathology and experimental neurology
container_volume 77
creator Ziemka-Nalecz, Malgorzata
Jaworska, Joanna
Sypecka, Joanna
Zalewska, Teresa
description Abstract Understanding the contribution of imbalance in protein acetylation levels and dysfunction of transcription to neurodegenerative diseases provides the rationale for the use of epigenetic modulators such as histone deacetylase (HDAC) inhibitors to combat neurodegenerative conditions. It is now widely recognized that various low-molecular weight HDAC inhibitors are broadly neuroprotective, preventing or delaying neuronal death and dysfunction in many rodent models of neurodegeneration. The beneficial effects result in part from modifications of histones and nonhistone proteins. This review describes evidence indicating that HDAC inhibitors have emerged as a promising new strategy in treating neurodegenerative disorders and summarizes treatment strategies from clinical trials currently underway.
doi_str_mv 10.1093/jnen/nly073
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2098768472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jnen/nly073</oup_id><sourcerecordid>2098768472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4913-dc13d360f32e501cd767b78002845c56444e86cb7fa8517602a4d05a601241883</originalsourceid><addsrcrecordid>eNp9kE1rFEEQQBsxmDV68i4DQhDCuNXfPV5CSMwHLsklnpvenlq3197ptXuGsP_eWSZ6EPRUl1evikfIOwqfKDR8vumwm3dxD5q_IDMqpaiV1OYlmQEwVnNQzTF5XcoGABpoxCtyzIEqqQybkcVtKH3qsLpC57HfR1ewuuvWYRn6lMvn6qJ6XGN2Oxz64KuvuK9CV93jkFNM34N3sboKJeUWczl_Q45WLhZ8-zxPyLfrL4-Xt_Xi4ebu8mJRe9FQXree8pYrWHGGEqhvtdJLbcZvjZBeKiEEGuWXeuWMpFoBc6IF6RRQJqgx_IR8nLy7nH4OWHq7DcVjjK7DNBTLoDFaGaHZiH74C92kIXfjd5Zx4GbMAAfh2UT5nErJuLK7HLYu7y0Fe4hsD5HtFHmk3z87h-UW2z_s76ojMJ-ApxT7McyPODxhtmt0sV__Q3k6baRh99_bvwDc7pQm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2303865608</pqid></control><display><type>article</type><title>Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Ziemka-Nalecz, Malgorzata ; Jaworska, Joanna ; Sypecka, Joanna ; Zalewska, Teresa</creator><creatorcontrib>Ziemka-Nalecz, Malgorzata ; Jaworska, Joanna ; Sypecka, Joanna ; Zalewska, Teresa</creatorcontrib><description>Abstract Understanding the contribution of imbalance in protein acetylation levels and dysfunction of transcription to neurodegenerative diseases provides the rationale for the use of epigenetic modulators such as histone deacetylase (HDAC) inhibitors to combat neurodegenerative conditions. It is now widely recognized that various low-molecular weight HDAC inhibitors are broadly neuroprotective, preventing or delaying neuronal death and dysfunction in many rodent models of neurodegeneration. The beneficial effects result in part from modifications of histones and nonhistone proteins. This review describes evidence indicating that HDAC inhibitors have emerged as a promising new strategy in treating neurodegenerative disorders and summarizes treatment strategies from clinical trials currently underway.</description><identifier>ISSN: 0022-3069</identifier><identifier>EISSN: 1554-6578</identifier><identifier>DOI: 10.1093/jnen/nly073</identifier><identifier>PMID: 30165682</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Neurodegeneration</subject><ispartof>Journal of neuropathology and experimental neurology, 2018-10, Vol.77 (10), p.855-870</ispartof><rights>2018 American Association of Neuropathologists, Inc. All rights reserved. 2018</rights><rights>2018 by American Association of Neuropathologists, Inc.</rights><rights>2018 American Association of Neuropathologists, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4913-dc13d360f32e501cd767b78002845c56444e86cb7fa8517602a4d05a601241883</citedby><cites>FETCH-LOGICAL-c4913-dc13d360f32e501cd767b78002845c56444e86cb7fa8517602a4d05a601241883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30165682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ziemka-Nalecz, Malgorzata</creatorcontrib><creatorcontrib>Jaworska, Joanna</creatorcontrib><creatorcontrib>Sypecka, Joanna</creatorcontrib><creatorcontrib>Zalewska, Teresa</creatorcontrib><title>Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?</title><title>Journal of neuropathology and experimental neurology</title><addtitle>J Neuropathol Exp Neurol</addtitle><description>Abstract Understanding the contribution of imbalance in protein acetylation levels and dysfunction of transcription to neurodegenerative diseases provides the rationale for the use of epigenetic modulators such as histone deacetylase (HDAC) inhibitors to combat neurodegenerative conditions. It is now widely recognized that various low-molecular weight HDAC inhibitors are broadly neuroprotective, preventing or delaying neuronal death and dysfunction in many rodent models of neurodegeneration. The beneficial effects result in part from modifications of histones and nonhistone proteins. This review describes evidence indicating that HDAC inhibitors have emerged as a promising new strategy in treating neurodegenerative disorders and summarizes treatment strategies from clinical trials currently underway.</description><subject>Neurodegeneration</subject><issn>0022-3069</issn><issn>1554-6578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE1rFEEQQBsxmDV68i4DQhDCuNXfPV5CSMwHLsklnpvenlq3197ptXuGsP_eWSZ6EPRUl1evikfIOwqfKDR8vumwm3dxD5q_IDMqpaiV1OYlmQEwVnNQzTF5XcoGABpoxCtyzIEqqQybkcVtKH3qsLpC57HfR1ewuuvWYRn6lMvn6qJ6XGN2Oxz64KuvuK9CV93jkFNM34N3sboKJeUWczl_Q45WLhZ8-zxPyLfrL4-Xt_Xi4ebu8mJRe9FQXree8pYrWHGGEqhvtdJLbcZvjZBeKiEEGuWXeuWMpFoBc6IF6RRQJqgx_IR8nLy7nH4OWHq7DcVjjK7DNBTLoDFaGaHZiH74C92kIXfjd5Zx4GbMAAfh2UT5nErJuLK7HLYu7y0Fe4hsD5HtFHmk3z87h-UW2z_s76ojMJ-ApxT7McyPODxhtmt0sV__Q3k6baRh99_bvwDc7pQm</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Ziemka-Nalecz, Malgorzata</creator><creator>Jaworska, Joanna</creator><creator>Sypecka, Joanna</creator><creator>Zalewska, Teresa</creator><general>Oxford University Press</general><general>by American Association of Neuropathologists, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20181001</creationdate><title>Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?</title><author>Ziemka-Nalecz, Malgorzata ; Jaworska, Joanna ; Sypecka, Joanna ; Zalewska, Teresa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4913-dc13d360f32e501cd767b78002845c56444e86cb7fa8517602a4d05a601241883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Neurodegeneration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ziemka-Nalecz, Malgorzata</creatorcontrib><creatorcontrib>Jaworska, Joanna</creatorcontrib><creatorcontrib>Sypecka, Joanna</creatorcontrib><creatorcontrib>Zalewska, Teresa</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuropathology and experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ziemka-Nalecz, Malgorzata</au><au>Jaworska, Joanna</au><au>Sypecka, Joanna</au><au>Zalewska, Teresa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?</atitle><jtitle>Journal of neuropathology and experimental neurology</jtitle><addtitle>J Neuropathol Exp Neurol</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>77</volume><issue>10</issue><spage>855</spage><epage>870</epage><pages>855-870</pages><issn>0022-3069</issn><eissn>1554-6578</eissn><abstract>Abstract Understanding the contribution of imbalance in protein acetylation levels and dysfunction of transcription to neurodegenerative diseases provides the rationale for the use of epigenetic modulators such as histone deacetylase (HDAC) inhibitors to combat neurodegenerative conditions. It is now widely recognized that various low-molecular weight HDAC inhibitors are broadly neuroprotective, preventing or delaying neuronal death and dysfunction in many rodent models of neurodegeneration. The beneficial effects result in part from modifications of histones and nonhistone proteins. This review describes evidence indicating that HDAC inhibitors have emerged as a promising new strategy in treating neurodegenerative disorders and summarizes treatment strategies from clinical trials currently underway.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>30165682</pmid><doi>10.1093/jnen/nly073</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3069
ispartof Journal of neuropathology and experimental neurology, 2018-10, Vol.77 (10), p.855-870
issn 0022-3069
1554-6578
language eng
recordid cdi_proquest_miscellaneous_2098768472
source Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)
subjects Neurodegeneration
title Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T21%3A25%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histone%20Deacetylase%20Inhibitors:%20A%20Therapeutic%20Key%20in%20Neurological%20Disorders?&rft.jtitle=Journal%20of%20neuropathology%20and%20experimental%20neurology&rft.au=Ziemka-Nalecz,%20Malgorzata&rft.date=2018-10-01&rft.volume=77&rft.issue=10&rft.spage=855&rft.epage=870&rft.pages=855-870&rft.issn=0022-3069&rft.eissn=1554-6578&rft_id=info:doi/10.1093/jnen/nly073&rft_dat=%3Cproquest_cross%3E2098768472%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4913-dc13d360f32e501cd767b78002845c56444e86cb7fa8517602a4d05a601241883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2303865608&rft_id=info:pmid/30165682&rft_oup_id=10.1093/jnen/nly073&rfr_iscdi=true